We examined whether replication-defective herpes simplex virus (HSV) vectors encoding the 67 kDa form of the glutamic acid decarboxylase (GAD 67 ) gene product, the g-aminobutyric acid (GABA) synthesis enzyme, can suppress detrusor overactivity (DO) in rats with spinal cord injury (SCI). One week after spinalization, HSV vectors expressing GAD and green fluorescent protein (GFP) (HSV-GAD) were injected into the bladder wall. Rats with SCI without HSV injection (HSVuntreated) and those injected with lacZ-encoding reporter gene HSV vectors (HSV-LacZ) were used as controls. Three weeks after viral injection, continuous cystometry was performed under awake conditions in all three groups. In the HSV-GAD group, the number and amplitude of non-voiding contractions (NVCs) were significantly decreased (40-45% and 38-40%, respectively) along with an increase in voiding efficiency, compared with HSV-untreated and HSV-LacZ groups, but micturition pressure was not different among the three groups. Intrathecal application of bicuculline partly reversed the decreased number and amplitude of NVCs, and decreased voiding efficiency in the HSV-GAD group. In the HSV-GAD group, GAD 67 mRNA and protein levels were significantly increased in the L6-S1 dorsal root ganglia (DRG) compared with the HSV-LacZ group, while 57% of DRG cells were GFPpositive, and these neurons showed increased GAD 67 -like immunoreactivity compared with the HSV-LacZ group. These results indicate that GAD gene therapy effectively suppresses DO after SCI predominantly through the activation of spinal GABA A receptors. Thus, HSV-based GAD gene transfer to bladder afferent pathways may represent a novel approach for treatment of neurogenic DO.
Introduction
Micturition depends on the coordinated activity of the urinary bladder and external urethral sphincter. 1 However, spinal cord injury (SCI) rostral to the lumbosacral level, which impairs voluntary and supraspinal control of voiding, disrupts this coordination. SCI initially induces areflexic bladder and urinary retention, followed by the emergence of automatic micturition and eventually detrusor overactivity (DO) mediated by spinal reflex mechanisms. Impaired bladder-sphincter coordination termed as detrusor-sphincter dyssynergia (DSD) reduces voiding efficiency, leading to urinary retention. 2 These lower urinary tract dysfunctions then lead to more serious problems, such as urinary incontinence, recurrent urinary tract infection and upper urinary tract deterioration.
In the central nervous system, glutamate is a major excitatory neurotransmitter, whereas glycine and g-aminobutyric acid (GABA) are the most abundant inhibitory amino-acid neurotransmitters. 3, 4 GABA is synthesized from glutamate by glutamic acid decarboxylase (GAD), 4 and is known to have an important role in the inhibitory regulation of micturition in normal spinal cord-intact rats. 5 Our recent study revealed that rats with chronic SCI had lower GAD 67 (67 kDa form of GAD) levels in the lumbosacral spinal cord and in the L6-S1 dorsal root ganglia (DRG), where bladder afferent fibers originate. These animals with SCI also showed DO on continuous cystometry, which was suppressed by intrathecally administered GABA receptor agonists. 6 Therefore, GABA is an important messenger in the inhibitory effect on micturition in rats with SCI, and hypofunction of inhibitory GABAergic neuronal activity in the spinal cord is likely to be involved in the genesis of DO after SCI.
Although baclofen, a GABA B receptor agonist, is approved for treatment of DO in patients with SCI, 7 this agent has not been widely used because the therapeutic window of this drug is modest and the dose is limited by side effects. One potential approach for increasing GABA levels in the spinal cord with limited side effects would be to use viral-mediated gene delivery so that the gene product of interest is delivered specifically to the DRG neurons or to the neighboring non-transduced neurons to which GABA can bind, which requires GABA to reduce DO. Herpes simplex virus (HSV) has several significant advantages over other viral vectors for treatment of peripheral nervous system disorders. 8 Replication-defective recombinant vectors, which lack multiple essential gene functions and, therefore, are nontoxic in vivo, 8, 9 have been constructed to reduce immune clearance of the vectors and increase the overall safety of the vector for clinical therapeutic application. It has been reported that replication-defective HSV-mediated gene transfer of GAD 67 delivered by subcutaneous inoculation can reduce neuropathic pain in spinal cord-hemisected or spinal nerve-ligated rats.
10,11 Therefore, we hypothesized that DO in rats with SCI might be suppressed if GABA levels are increased using replication-defective HSV-mediated gene transfer of GAD in bladder afferent pathways.
Thus, in this study, we investigated the feasibility of HSV vector-mediated GAD 67 gene therapy for treatment of DO after SCI. We examined bladder activity and confirmed vector-mediated GAD 67 gene delivery by measuring the expressions of GAD 67 mRNA and protein, as well as immunoreactivity of GAD 67 , in L6-S1 DRG after SCI and HSV vector administration.
Results
Comparisons of bladder activity in HSV-untreated, HSV-LacZ, and HSV-GAD groups Representative traces of continuous cystometry in lacZencoding reporter gene HSV vectors (HSV-LacZ) and HSV-GAD groups are shown in Figure 1 . In HSVuntreated and HSV-LacZ groups, all spinalized rats showed many non-voiding contractions (NVCs) before large-amplitude voiding bladder contractions occurred. There were no significant differences in cystometric parameters between HSV-untreated and HSV-LacZ groups (Table 1) . However, in the HSV-GAD group (3 weeks after viral injection), the number of NVCs was significantly decreased by 37-43% (Po0.01) compared with HSV-untreated or HSV-LacZ groups (Table 1 , Figure 2a ). The amplitude of NVCs was also significantly reduced by 39-41% (Po0.01) in the HSV-GAD group compared with that in HSV-untreated and HSV-LacZ groups (Table 1, Figure 2b ). In addition, the residual volume and voiding efficiency were significantly (Po0.05) decreased and increased, respectively, in the HSV-GAD group compared with those in HSV-untreated and HSV-LacZ groups. However, maximal voiding pressure (MVP), voided volume or bladder capacity was not significantly different among the three groups (Table 1, Figure 2c ).
Changes in bladder activity after an intrathecal application of GABA receptor antagonists in the HSV-GAD group
In the HSV-GAD group (3 weeks after viral injection), continuous cystometry showed a reduction in the number and amplitude of NVCs (Figure 3a) . However, after an intrathecal application of bicuculline (0.1 mg), the number and amplitude of NVCs were significantly (Po0.05) increased ( Figure 3b ; Table 2 ), and there were no significant differences in the number of NVCs between untreated HSV-LacZ and bicuculline-treated HSV-GAD rats (4.38±0.46 vs 6.00±2.02, P ¼ 0.46). However, the amplitude of NVC was still lower in the HSV-GAD group after an intrathecal application of bicuculline compared with that in the HSV-LacZ group (13.1 ± 0.8 vs 28.3±3.4, Po0.01). After an intrathecal application of bicuculline, MVP was not changed, whereas voiding efficiency was reduced in HSV-GAD-treated rats (Table  2) . In a separate group of HSV-GAD-treated rats, an intrathecal application of saclofen (1 mg) did not affect any cystometric parameters ( Table 2) .
Comparisons of the GAD 67 mRNA level in L6-S1 DRG between HSV-LacZ and HSV-GAD groups A reverse transcription-PCR study was carried out to examine the expression levels of GAD 67 mRNA in L6-S1 DRG. In the HSV-GAD group (3 weeks after viral Gene therapy for detrusor overactivity M Miyazato et al injection), the GAD 67 mRNA/b-actin mRNA ratio in L6-S1 DRG was significantly higher (1.29±0.14, P ¼ 0.015) compared with the HSV-LacZ group (0.74 ± 0.08) (Figure 4a ), using primer pairs specific for the GAD 67 and b-actin mRNAs.
Comparisons of the GAD 67 protein level of L6-S1 DRG between HSV-LacZ and HSV-GAD groups
In the next step, western blot analysis was carried out to evaluate the GAD 67 protein expression levels in L6-S1 DRG 3 weeks after treatment with the different vectors. The bands of GAD 67 and GAPDH were visualized at 67 and 37 kDa, respectively, and the intensities of the bands were determined as per Materials and methods. In the HSV-GAD group (3 weeks after viral injection), the band density of GAD 67 protein relative to that of GAPDH was significantly higher (0.44±0.03, P ¼ 0.016) compared with the HSV-LacZ group (0.35 ± 0.02) (Figure 4b ), which correlates with the increase in GAD 67 -specific message detected by qPCR (Figure 4a ).
GFP transgene expression in the HSV-GAD group and comparison of the GAD 67 expression in HSV-LacZ and HSV-GAD groups
To confirm the efficiency of HSV vector transduction into sensory nerves after SCI (3 weeks after viral injection), the expression profile of the marker gene, green fluorescent protein (GFP), in L6-S1 DRG was investigated. In three DRG sections randomly selected from each of the four HSV-GAD-injected animals, GFP Gene therapy for detrusor overactivity M Miyazato et al immunoreactivity (that is, grade 2 or 3 staining intensity) was observed in 57.4±6.4% of DRG cells per section ( Figure 5a ). In the HSV-GAD group, the number of small-and medium-sized (o35 mm in diameter) GAD 67 -positive cells was increased in L6-S1 DRG neurons compared with the HSV-LacZ group (Figure 5b ). In three DRG sections randomly selected from each of four HSV-GAD animals, 42.6 ± 8.4% of DRG cells per section were GAD 67 -positive (that is, grades 2 or 3 staining intensity), whereas GAD 67 -positive DRG neurons were found in only 13.8±1.4% of DRG cells per section in HSV-LacZ rats.
Discussion
This study indicates that (1) HSV-GAD treatment inhibits DO, as evidenced by a reduction in NVCs without affecting voiding in rats with SCI; (2) intrathecal administration of the GABA A receptor antagonist, bicuculline, partly restores DO, as evidenced by the induction of large NVCs in HSV-GAD-treated rats with SCI; (3) 57% of L6-S1 DRG cells where bladder afferents originate express a reporter gene within the vector, as evidenced by GFP-positive staining after HSV-GAD treatment; and (4) the expression of GAD 67 , the GABAsynthesizing enzyme, is increased in the L6-S1 DRG after Table 2 Cystometric parameters before and after intrathecal administration of bicuculline or saclofen in the HSV-GAD group Values are the mean ± s.e. *Po0.05 when compared between HSVLacZ-and HSV-GAD-treated rats with SCI. (b) GAD 67 protein intensity compared with GAPDH assessed by western blot analysis in HSV-GAD-treated versus HSV-LacZ-treated rats with SCI (n ¼ 4 per each group). The intensity of GAD 67 protein was increased in HSV-GAD-treated rats with SCI compared with that in HSV-LacZtreated rats with SCI, but that of GAPDH was not different between two groups. HSV, herpes simplex virus; LacZ, b-galactosidase; GAD, glutamic acid decarboxylase; DRG, dorsal root ganglia; SCI, spinal cord injury.
HSV-LacZ
Gene therapy for detrusor overactivity M Miyazato et al HSV-GAD treatment, as evidenced by increased GAD 67 mRNA and protein levels. Thus, HSV vectors can be efficiently transported to bladder afferent pathways and inhibit DO predominantly through GABA A receptor activation. The organization of the micturition reflex undergoes marked changes after SCI: owing to the disruption of supraspinal micturition reflex pathways, a spinal micturition reflex is unmasked, resulting in DO. Earlier work by our group 6, 12 and others 5 have suggested that the GABA modifier, GAD, was reduced after SCI, suggesting that a therapeutic approach to deliver a gene product involved in GABA synthesis may prove useful in altering the micturition pattern in SCI. Moreover, our earlier work using HSV vectors has shown that vector administered to the rat's bladder wall very efficiently transduces the bladder muscle layer and L6-S1 DRG neurons, as evidenced by expression of the reporter gene (Escherichia coli lacZ) product, and is capable of expressing a variety of therapeutic gene products. [13] [14] [15] These studies, along with the use of the same HSV-GAD vector to treat neuropathic pain associated with other forms of SCI, provided the underpinning for the current study.
In our recent study, an intrathecal application of muscimol and baclofen (GABA A and GABA B receptor agonists, respectively) inhibited NCVs as well as MVP in rats with SCI. 6 In contrast, this study showed that GAD gene therapy using replication-defective HSV vectors (HSV-GAD) was effective in reducing the number and amplitude of NVCs (DO) without affecting MVP in rats with SCI. As decreased NVCs (DO) and bladder contractility (that is, a reduction in MVP) are assumed to reflect the suppression of afferent and efferent activity in the micturition reflex pathway, respectively, 2 HSV-GAD treatment is likely to predominantly inhibit the afferent limb of the micturition reflex. Thus, this suggests that GAD gene therapy using HSV vectors can target bladder afferent pathways rather efferent pathways when injected into the bladder. It is well known that two types of afferent fibers, namely Ad and C-fibers, carry sensory information from the bladder to the spinal cord. 16, 17 In cats and rats, Ad-fiber bladder afferents trigger normal micturition through a long latency supraspinal pathway passing through the pons. 2, 17 In rats with chronic SCI, C-fiber afferents appear to initiate DO, although Ad bladder afferents still trigger the voiding reflex.
2,17 Desensitizing C-fiber afferents by systemic capsaicin administration suppressed NVCs without affecting the voiding reflex in rats with chronic SCI. 18 This capsaicin effect is similar to that seen in the current experiments (that is, reduced NVCs without affecting voiding) after GAD gene therapy in rats with SCI, suggesting that GAD gene therapy preferentially inhibits DO by suppressing C-fiber bladder afferents without affecting Ad-fiber-dependent voiding contractions. Therefore, GAD gene therapy using non-replicating HSV vectors that can improve urine storage function without affecting voiding function would be more beneficial than systemic or intrathecal drug therapy for treatment of urinary problems in SCI patients because of the specificity of the afferents involved.
Our therapeutic strategy takes advantage of the natural neurotropism of HSV. It has adapted itself to infect neurons of the peripheral nervous system and remain in a latent or quiescent state within these neurons for the life of the host. 19 Replication-defective vectors can be used to deliver and express genes in the peripheral and the central nervous systems. The ability of the virus to establish a latent infection does not depend on viral gene expression. Thus, non-cytotoxic, replication-defective vectors can be used, which adds a measure of safety to the therapeutic application. We also used the strong HCMV promoter to drive the expression of GAD. Expression from this promoter is transient, typically lasting 7-21 days after infection depending on the animal model and tissue. If longer-term expression of GAD is required to achieve the desired effect, HSV already possesses a natural promoter system LAP2 that is active at lower, yet-significant long-term levels in the nervous system. [20] [21] [22] In this study, we evaluated cystometric parameters 3 weeks after HSV-GAD injection because, in our preliminary data, DO (that is, NVCs) was not suppressed 2 weeks after HSV-GAD injection in rats with SCI (data not shown). However, in our earlier study, HSV vectors encoding the preproenkephalin genes (SHPE), which were injected into the bladder wall of normal rats, elevated the preproenkephalin gene expression in L6-S1 DRG and reduced bladder hyperactivity induced by capsaicin 1 week after viral injection. 13 Although the reason for the delayed onset of HSV treatment efficacy in animals with SCI is not known, the efficiency of gene Gene therapy for detrusor overactivity M Miyazato et al delivery and transfer to the nerves may be reduced because of sparse distribution of nerves in the bladder owing to bladder distension and smooth muscle hypertrophy induced after SCI. This difference in the onset of therapeutic effect may also relate to the nature of the transgene and its role in synthesizing either met-and leu-enkephalin in the case of SHPE or GABA in the case of the QHGAD 67 vector, the release of these peptides and their action. In addition, although we did not measure GABA production in this study, our earlier study showed that the amount of GABA released at the dorsal spinal cord from the central terminals of DRG transduced by subcutaneous inoculation into the foot is increased in QHGAD 67 -treated rats compared with those treated with the control vector. 10 The current study also showed that intrathecal bicuculline partly restored NVCs without affecting MVP, whereas intrathecal saclofen did not affect cystometric parameters in HSV-GAD-treated rats with SCI. In contrast, in our earlier study, intrathecal muscimol and baclofen at the level of L6-S1 spinal cord reduced NVCs in rats with SCI, and the effects were antagonized by bicuculline and saclofen, respectively, indicating that both GABA A and GABA B receptors are involved in the suppression of DO in SCI. 6 GABA reportedly inhibits bladder activity by acting through at least four distinct sites in spinalized rats: (1) at the spinal level, by reducing afferent inputs from the detrusor through afferent nerves; (2) at the sacral parasympathetic nucleus, by inhibiting the neurons; (3) at the pelvic ganglionic level, by inhibiting excitatory neurotransmission; and (4) at the postganglionic level, by reducing neurotransmitter release from neurons innervating the detrusor. 23 Thus, it seems reasonable to assume that GABA A receptor activation primarily contributes to the suppression of sensory inputs through C-fiber bladder afferent pathways in the spinal cord after HSV-GAD treatment in rats with SCI.
A decrease in GABA A receptor-mediated inhibitory postsynaptic potentials, a reduction in GAD 65 expression and apoptosis in the dorsal horn of the spinal cord have been reported in chronic nerve injury models of neuropathic pain. 24 We also found earlier that the GAD 67 mRNA level in the L6-S1 spinal cord and DRG was significantly decreased after SCI. 6 Thus, hypofunction of the GABAergic inhibitory system is, at least in part, responsible for development of DO after SCI. Therefore, it is likely that GABA supplemental therapy represents a reasonable approach for treating DO after SCI. However, the ubiquitous distribution of GABA receptors in the central nervous system results in side effects, which impose severe restriction on the dose of GABA receptor agonists, such as baclofen, even when administered intrathecally as an attempt to control DO after SCI. 7 These complications may be avoided by inducing the expression of neurotransmitters in a specific population of neurons. In this study, after HSV-GAD injection in the bladder wall, the GAD expression was increased in L6-S1 DRG, which contains bladder afferent neurons, and C-fiber-dependent DO was suppressed even though the Margolis lab has shown that the vector can infect both Aq-fibers as well as peptidergic small unmyelinated C-fibers, which project to lamina I and lamina IIo, and non-peptidergic small-to-medium unmyelinated C-fibers, which project to lamina IIiC. 25 , 26 Liu et al. 10 have reported that replication-defective HSVmediated gene transfer of GAD delivered by subcutaneous inoculation can increase the release of GABA in the spinal cord, and can reduce neuropathic pain in spinal cord hemisection rats. Therefore, HSV-GAD vector injection into the bladder wall could lead to a local increase in GABA synthesis in bladder afferent pathways. We have also reported that nerve growth factor expression in afferent pathways occurs in L6-S1 DRG after HSV-mediated nerve growth factor gene delivery into the bladder wall, but not in adjacent DRGs in rats. 14 This suggested that GAD gene therapy using HSV vectors can target the treated organ and can be efficiently transported to its afferent pathways with limited side effects.
We also found that in the HSV-GAD group, HSVmediated GAD gene delivery into the bladder wall decreased the residual volume and increased voiding efficiency, compared with HSV-untreated or HSV-LacZtreated rats with SCI. However, no differences were observed in MVP among HSV-untreated, HSV-LacZ and HSV-GAD groups. These results suggest that HSVmediated GAD gene delivery reduces urethral resistance during voiding, resulting in improved residual volume and voiding efficiency. Our earlier study indicated that the hyperexcitability of C-fiber bladder afferents is involved in DSD (that is, simultaneous urethral sphincter contraction during bladder contraction) after SCI because C-fiber desensitization by capsaicin pretreatment reduces urethral contraction pressure during bladder contraction in rats with SCI. 27 We also recently reported that an intrathecal application of GABA receptor agonists can suppress DSD in rats with SCI. 12 Therefore, suppression of the C-fiber bladder afferent activity after HSVmediated GAD gene delivery may also have an inhibitory effect on DSD in SCI, although further studies are needed to clarify this point.
In conclusion, this study provides the first evidence of the efficacy of GAD gene therapy using replicationdefective HSV vectors for DO after SCI. GAD gene therapy mainly inhibits C-fiber bladder afferent pathways to exert its effects predominantly through GABA A receptors. Therefore, the novel GAD gene therapy using replication-defective HSV vectors could be effective for treatment of DO by restoring impaired GABA mechanisms in patients with SCI. The ultimate goal of these studies is to use an HSV vector-based approach in human clinical trials.
Materials and methods

Animal model
A total of 38 adult female Sprague-Dawley rats (weighing 236-270 g) were used according to the experimental protocol approved by the University of Pittsburgh Institutional Animal Care and Use Committee. To induce SCI, rats were anesthetized with pentobarbital (30 mg kg À1 , i.p., Ovation, Deerfield, IL, USA) and Th9 laminectomy was performed. The dura was opened and the complete transection of the T9-T10 spinal cord was performed with scissors. A sterile Surgifoam sponge (Ferrosan, Soeborg, Denmark) was placed between the cut ends of the spinal cord. The overlying muscle and skin were then sutured to close the wound. Rats were Gene therapy for detrusor overactivity M Miyazato et al then put on an electric warmer to maintain body temperature and were allowed to recover from anesthesia. Animals with SCI were postoperatively treated with ampicillin (100 mg kg À1 , i.m.) for 5 days. The bladder of spinalized rats was emptied by abdominal compression twice a day until reflex voiding recovered, usually 10-14 days after spinalization. Rats with SCI were divided into the following three groups: (1) rats with SCI without HSV injection (HSV-untreated, n ¼ 10); (2) rats with SCI with replication-defective HSV vector Q0ZHG (control vector) administration (HSV-LacZ, n ¼ 10); and (3) rats with SCI with replication-defective, GAD 67 -expressig HSV vector QHGAD 67 administration (HSV-GAD, n ¼ 18).
Viral vectors and in vivo viral administration
The QHGAD 67 vector (HSV-GAD) was constructed through recombination of the transfer plasmid containing the GAD 67 cDNA under the control of the human cytomegalovirus (HCMV) immediate early promoter into the U L 41 gene locus of QOZHG as previously described ( Figure 6 ). 10 The replication-defective vectors, QHGAD 67 and Q0ZHG, were propagated on the 7b cell line, 28 which supplies both ICP4 and ICP27 in trans. Both QHGAD 67 and Q0ZHG express the GFP, whereas the Q0ZHG (HSV-LacZ) control vector also expresses lacZ.
In HSV-LacZ and HSV-GAD groups, animals were anesthetized with pentobarbital (30 mg kg À1 ) 1 week after SCI. A lower abdominal incision was made to expose the bladder, and the vectors were injected into the bladder wall using a 30-G Hamilton syringe (10 ml, Hamilton, Reno, NV, USA). A total of 40 ml viral suspension (2 Â 10 7 plaque-forming units (PFU) in total) of either Q0ZHG or QHGAD 67 was injected at four sites of the bladder wall around the bladder base. After the abdomen was closed, rats were allowed to recover from anesthesia and were housed in an approved Biosafety Level 2 animal facility.
Surgical procedure for experiments
In the three groups, 4 weeks after SCI and 3 weeks after vector treatment, the animals were anesthetized with 2% isoflurane, and the abdomen was opened through midline laparotomy in the experiment nos. 1 and 2 described below. The ureters were transected at the level of the aortic bifurcation, and the distal ends were ligated. 27, 29 A polyethylene catheter (PE-90, Clay-Adams, Parsippany, NJ, USA) was inserted into the bladder through the bladder dome to record intravesical pressure. After the abdomen was closed, the rats were placed in a restrainer (Braintree Scientific Inc., Braintree, MA, USA) and were allowed to recover from anesthesia for 1-2 h.
For eight rats with SCI of the HSV-GAD group (Experiment no. 2), a laminectomy was performed at the level of the third lumbar vertebra under isoflurane anesthesia 1-2 days before cystometry. A PE-10 catheter was implanted intrathecally at the level of the L6-S1 spinal cord through a small hole of the dura. The end of the catheter was heat-sealed and placed subcutaneously. The implanted intrathecal catheter was exteriorized through the skin incision for drug administration when cystometry was performed.
Administration of drugs
For intrathecal application in Experiment no. 2, 1 ml of drug solution was given through the implanted intrathecal catheter and flushed with 10 ml of saline. After the experiments, 2 ml of Evans blue flushed with 10 ml of saline was injected intrathecally, the position of the intrathecal catheter was checked in all animals, and the extent of dye distribution in the subarachnoid space was evaluated. (À)-Bicuculline methobromide and saclofen (Tocris Cookson Inc., Ellisville, MO, USA) were dissolved in distilled water. Intrathecal catheter implantation or vehicle (saline or distilled water) application did not alter bladder activity during cystometry in rats with SCI (data not shown).
Experiment no. 1: cystometry in an awake condition (n ¼ 10 each of three groups). The intravesical catheter was connected to a pressure transducer and an infusion pump through a three-way stopcock. Physiological saline at room temperature was infused at a rate of 0.08 ml min À1 to elicit repetitive bladder contractions. Cystometric parameters were recorded after at least two stable micturition cycles were observed. 6 The number and amplitude of NVCs were measured during a 2-to 4-min period before micturition. NVCs Gene therapy for detrusor overactivity M Miyazato et al were defined as rhythmic intravesical pressure increases 47 cm H 2 O from baseline pressure without the release of fluid from the urethra. MVP was also measured. Saline volume from the urethral meatus during voiding was collected and measured to determine voided volume. After each voiding, the infusion was stopped and residual volume was measured. Residual saline was withdrawn through the intravesical catheter by gravity and then the bladder was completely emptied by manual compression through the abdominal wall. Bladder capacity was calculated as the sum of voided volume and residual volume. Voiding efficiency was then calculated using the formula: voiding efficiency (%) ¼ [(voided volume/bladder capacity) Â 100].
Experiment no. 2: awake cystometry before and after GABA receptor antagonists in the HSV-GAD group. To examine the effect of GAD 67 delivery, (À)Àbicuculline methobromide (GABA A antagonist; 0.1 mg; n ¼ 4) or saclofen (GABA B antagonist; 1 mg; n ¼ 4) was administered through the intrathecal catheter using a Hamilton microsyringe in the HSV-GAD group. Then cystometric parameters were compared before and after the administration of GABA receptor antagonists.
Experiment no. 3: quantification of GAD 67 mRNA in HSV-LacZ and HSV-GAD groups (n ¼ 6 each). After cystometry, L6-S1 DRG were rapidly removed, and total RNA was extracted from the pooled DRG using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA (1 mg) was reverse-transcribed into cDNA using Superscript II (Invitrogen). Primers for GAD 67 (GAD 67 forward primer, 5 0 -GCGGGAGCGGATCCTAATA-3 0 and reverse primer, 5 0 -TGGTGCATCCATGGGCTAC-3 0 ). 10 and b-actin (Ambion, Austin, TX, USA) were used. The GAD 67 and b-actin mRNA levels were quantified with an MX3000P real-time PCR system (Stratagene, La Jolla, CA, USA) in a 25 ml volume, using SYBR Green PCR Master Mix (QIAGEN, Valencia, CA, USA). Amplification of cDNA was performed under the following condition: one cycle of 95 1C for 15 min, followed by 40 cycles of 1 min at 95 1C, 1 min at 55 1C and 1 min at 72 1C for both GAD 67 and b-actin. Specificity of GAD 67 in DRG was confirmed by melting curve analysis. Standard curves constructed from serial dilution of cDNA in each tissue were analyzed with an MX3000P real-time PCR system. Quantification of the samples was achieved from the threshold cycle by interpolation from the standard curve to calculate a copy number for GAD 67 , and the ratio of GAD 67 to b-actin mRNA was compared.
Experiment no. 4: western blot analysis of HSV-LacZ and HSV-GAD groups (n ¼ 4 each). L6-S1 DRG were sonicated in RIPA (radioimmunoprecipitation assay) buffer containing 1 Â RIPA lysis buffer, phenylmethylsulfonyl fluoride, sodium orthovanadate and protease inhibitor cocktail (0.3 ml/100 mg tissue; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The homogenate was centrifuged at 10 000 r.p.m. for 10 min at 4 1C. The supernatant was collected, and the protein was determined by the Bradford method using a protein assay kit (Pierce Biotechnology, Rockford, IL, USA), with bovine serum albumin as a standard. For each sample, 30 mg of the protein extracts were subjected to a standard 12% Tris-HCl PAGE-Gel (Bio-Rad Laboratories Inc., Hercules, CA, USA). After electrophoresis, proteins were transferred to nitrocellulose membrane (Bio-Rad Laboratories Inc.). The nitrocellulose blots were blocked overnight at 4 1C with 5% dry milk (Nestle, Glendale, CA, USA) in phosphate-buffered saline (PBS) with 0.05% Tween-20 and incubated with rabbit anti-GAD 67 (1:1000; Chemicon, Temecula, CA, USA) for 2 h at room temperature, followed by horseradish peroxidase-conjugated goat anti-rabbit (1:1000; Vector Labs, Burlingame, CA, USA) for 2 h at room temperature. Western blot was visualized using an ECL detection system (GE Healthcare, Buckinghamshire, UK). The membrane was stripped and re-probed with rabbit anti-GAPDH (Santa Cruz Biotechnology) as a loading control. The intensity of each band was determined by quantitative densitometry using VersaDoc image acquisition and analysis software (Bio-Rad Laboratories Inc.).
Experiment no. 5: immunohistochemistry in HSV-LacZ and HSV-GAD groups (n ¼ 4 each). Rats randomly selected from the HSV-LacZ and HSV-GAD groups (n ¼ 4 each) were perfused intracardially with 4% paraformaldehyde solution in 0.16% picric acid and 0.1 M phosphate buffer, and L6-S1 DRG were removed, which were postfixed in the same solution for about 48 h, and then immersed in 0.1 M phosphate buffer containing 25% sucrose for about 48 h. Serial sections were cut at 14-mm thickness on a cryostat and thaw-mounted onto cold Superfrost microscope slides (Fisher Scientific, Pittsburgh, PA, USA). The sections were air-dried, rinsed in 0.01 M (PBS) and then pre-incubated for 1 h in 0.1 M PBS containing 2% normal donkey serum and 0.5% Triton X-100 (PBDT). The sections were then incubated overnight with primary antibodies diluted in PBDT in a humidity chamber at 4 1C. A negative control was prepared by using PBDT without primary antibodies. The following primary antibodies were used: rabbit anti-GFP (1:200; Santa Cruz Biotechnology) or rabbit anti-GAD 67 (1:1000, Chemicon). After rinsing in 0.01 M PBS, the sections were incubated with biotinylated anti-rabbit IgG (immunoglobulin G) (1:200; Vector Labs) and anti-rabbit fluorescent Cy3-conjugated fragment IgG (1:600, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) diluted in PBDT for 2 h at room temperature for GFP and GAD 67 stainings, respectively. After rinsing in 0.01 M PBS, the sections were incubated with Alexa Fluor 488-conjugated streptavidin (1:600; Molecular Probes Invitrogen, Carlsbad, CA, USA) diluted in PBDT for 2 h at room temperature for GFP staining. After rinsing in 0.01 M PBS, the sections were coverslipped. The distribution of GFP and GAD 67 immunoreactivity in DRG neuronal profiles was analyzed under fluorescence illumination with FITC (fluorescein isothiocyanate) and Cy3 filters, respectively. Fluorescent images were captured directly off the microscope using a digital camera. The intensity of GFP or GAD 67 immunoreactivity was rated on a 4-point scale, from completely negative (grade 0) to intense staining (grade 3), and the neurons that exhibited grade 2 or 3 were regarded as positively stained cells. We also counted the number of GFP-or GAD-positive cells among DRG neurons, in which their nuclei were clearly seen, to avoid the counting of non-neuronal staining. The number of GFP-or GAD 67 -positive cells, as well as the Gene therapy for detrusor overactivity M Miyazato et al total DRG neurons in each 14-mm-thick DRG section, was counted, and the percent ratio of positively stained cells against the total DRG cells per section was calculated and then averaged.
Statistical analysis
Data are expressed as the mean ± s.e. Statistical comparisons were performed by paired or unpaired t-test, as well as by the Wilcoxon test, where applicable, with Po0.05 considered statistically significant.
